Clinical Trial Update: A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Describes a Phase 1 clinical trial of SPX-303, a bispecific antibody targeting LILRB2 and PD-L1, in patients with solid tumors, including head and neck squamous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• SPX-303

Snippet

Sponsor: SparX Biotech(Jiangsu) Co., Ltd. | Conditions: Solid Tumor, HNSCC | Phase 1 | Status: RECRUITING